Id: acc0519
Group: 1sens
Protein: beta-catenin
Gene Symbol: CTNNB1
Protein Id: P35222
Protein Name: CTNB1_HUMAN
PTM: phosphorylation
Site: Tyr654
Site Sequence: HSRNEGVATYAAAVLFRMSED
Disease Category: Cancer
Disease: Thyroid Cancer
Disease Subtype: anaplastic thyroid carcinoma
Disease Cellline: SW1736
Disease Info:
Drug: I131
Drug Info: "Iodine-131 (I-131) is a radioactive isotope used as a therapeutic agent for hyperthyroidism and thyroid cancer, functioning by emitting beta radiation to selectively destroy overactive thyroid cells or malignant thyroid tissue, with a physical half-life of approximately 8 days and administered orally or intravenously as a radiopharmaceutical. "
Effect: inhibit
Effect Info: "ATRA treatment reduced the phosphorylation of beta-catenin (Ser45 and Y654) and GSK-3beta (Ser9), thereby enhancing the sensitivity of undifferentiated thyroid cancer to isotopic therapy."
Note: Non-conventional drugs
Score: 4.5
Pubmed(PMID): 29344218
Sentence Index:
Sentence:

Sequence & Structure:

MATQADLMELDMAMEPDRKAAVSHWQQQSYLDSGIHSGATTTAPSLSGKGNPEEEDVDTSQVLYEWEQGFSQSFTQEQVADIDGQYAMTRAQRVRAAMFPETLDEGMQIPSTQFDAAHPTNVQRLAEPSQMLKHAVVNLINYQDDAELATRAIPELTKLLNDEDQVVVNKAAVMVHQLSKKEASRHAIMRSPQMVSAIVRTMQNTNDVETARCTAGTLHNLSHHREGLLAIFKSGGIPALVKMLGSPVDSVLFYAITTLHNLLLHQEGAKMAVRLAGGLQKMVALLNKTNVKFLAITTDCLQILAYGNQESKLIILASGGPQALVNIMRTYTYEKLLWTTSRVLKVLSVCSSNKPAIVEAGGMQALGLHLTDPSQRLVQNCLWTLRNLSDAATKQEGMEGLLGTLVQLLGSDDINVVTCAAGILSNLTCNNYKNKMMVCQVGGIEALVRTVLRAGDREDITEPAICALRHLTSRHQEAEMAQNAVRLHYGLPVVVKLLHPPSHWPLIKATVGLIRNLALCPANHAPLREQGAIPRLVQLLVRAHQDTQRRTSMGGTQQQFVEGVRMEEIVEGCTGALHILARDVHNRIVIRGLNTIPLFVQLLYSPIENIQRVAAGVLCELAQDKEAAEAIEAEGATAPLTELLHSRNEGVATYAAAVLFRMSEDKPQDYKKRLSVELTSSLFRTEPMAWNETADLGLDIGAQGEPLGYRQDDPSYRSFHSGGYGQDALGMDPMMEHEMGGHHPGADYPVDGLPDLGHAQDLMDGLPPGDSNQLAWFDTDL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Withdrawn colorectal adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 2 Recruiting cirrhosis of liver ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed acute myeloid leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed chronic myelogenous leukemia ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Terminated neoplasm ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic carcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed pancreatic adenocarcinoma ClinicalTrials
CTNNB1 PRI-724 CBP/beta catenin inhibitor 1 Completed Malignant Pancreatic Neoplasm ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CTNNB1-Ser179
Cancer Intensity
BRCA -0.962
COAD 0.455
HGSC 1.973
ccRCC -1.319
GBM -0.972
HNSC 0.229
LUAD
LUSC
non_ccRCC -0.072
PDAC 0.409
UCEC 0.257
CTNNB1-Ser191
Cancer Intensity
BRCA -1.014
COAD -0.344
HGSC 0.922
ccRCC -0.101
GBM 0.311
HNSC 0.693
LUAD 0.681
LUSC 0.136
non_ccRCC 1.119
PDAC -2.383
UCEC -0.021
CTNNB1-Ser222
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.549
HNSC
LUAD -0.77
LUSC 1.445
non_ccRCC
PDAC
UCEC -0.126
CTNNB1-Ser33
Cancer Intensity
BRCA
COAD
HGSC -1.746
ccRCC 0.213
GBM 1.104
HNSC -0.324
LUAD -0.011
LUSC
non_ccRCC
PDAC
UCEC 0.764
CTNNB1-Ser37
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.655
GBM 1.477
HNSC -0.252
LUAD -0.57
LUSC
non_ccRCC
PDAC
UCEC
CTNNB1-Ser45
Cancer Intensity
BRCA
COAD -0.184
HGSC -1.332
ccRCC
GBM 0.613
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.904
CTNNB1-Ser552
Cancer Intensity
BRCA -1.793
COAD -0.07
HGSC 0.724
ccRCC 1.879
GBM -0.666
HNSC 0.383
LUAD 0.034
LUSC
non_ccRCC
PDAC -0.172
UCEC -0.318
CTNNB1-Ser675
Cancer Intensity
BRCA -0.341
COAD -0.152
HGSC 2.444
ccRCC -0.185
GBM 0.26
HNSC 0.094
LUAD -0.329
LUSC 0.129
non_ccRCC -0.617
PDAC -1.752
UCEC 0.448
CTNNB1-Thr217
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.319
HNSC 0.802
LUAD -1.121
LUSC
non_ccRCC
PDAC
UCEC
CTNNB1-Thr40
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC
GBM 0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
CTNNB1-Thr41
Cancer Intensity
BRCA
COAD
HGSC 0.385
ccRCC
GBM 0.75
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -1.135
CTNNB1-Thr551
Cancer Intensity
BRCA
COAD 0.362
HGSC -1.588
ccRCC
GBM
HNSC 0.735
LUAD 0.046
LUSC 1.147
non_ccRCC
PDAC
UCEC -0.701
CTNNB1-Thr556
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
CTNNB1-Tyr30
Cancer Intensity
BRCA
COAD
HGSC 0.707
ccRCC
GBM
HNSC
LUAD -0.707
LUSC
non_ccRCC
PDAC
UCEC
CTNNB1-Tyr716
Cancer Intensity
BRCA
COAD -0.807
HGSC 1.119
ccRCC
GBM -0.312
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
Y 654 P Intestinal cancer Phosphorylation 21307168
Y 654 U Idiopathic pulmonary fibrosis Phosphorylation 19104148
Y 654 U Nasopharyngeal carcinoma Phosphorylation 37496925

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: